Clinical trial
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large…
NCT00216164 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00216164 |
|---|---|
| Title | Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Official title | Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64 |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Eli Lilly and Company Industry Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | Rituximab, Gemcitabine |
| Enrollment | 8 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: